Firstly, the current analysis is one of the first cost-effectiveness analyses, using real-world clinical input data, of adjuvant trastuzumab for one year in early female HER2-positive breast cancer and the first one in a Cyprus setting. Here, ERBB2 is linked to breast cancer.